> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-144/
- Published: 2017-08-13T12:00:00.000Z
- Updated: 2026-09-14T22:40:50.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139375

[**Guidance on Medical Device Development Tools**](https://www.fdaweb.com/guidance-on-medical-device-development-tools/)  
*Federal Register* notice: FDA announces the availability of a guidance on “Qualification of Medical Device Development Tools (MDDT)” that is intended to finalize the MDDT program. 08/10/2017

[**Guide on Expiry Dating for Unit Dose Repackaging**](https://www.fdaweb.com/guide-on-expiry-dating-for-unit-dose-repackaging/)  
*Federal Register* notice: FDA announces the availability of a revised draft guidance on “Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products.” 08/09/2017

[**FDA Guide on CMC Postapproval Changes for BLAs**](https://www.fdaweb.com/fda-guide-on-cmc-postapproval-changes-for-blas/)  
*Federal Register* notice: FDA makes available a draft guidance on “CMC Postapproval Manufacturing Changes for Specified Biological Products To Be Documented in Annual Reports.” 08/09/2017

[**Comments Sought on Biologic Manufacturing Arrangements**](https://www.fdaweb.com/comments-sought-on-biologic-manufacturing-arrangements/)  
*Federal Register* notice: FDA seeks comments on an information collection extension for its “Guidance for Industry: Cooperative Manufacturing Arrangements for Licensed Biologics.” 08/08/2017

[**Comments Sought on Drug Ad Information Requirements**](https://www.fdaweb.com/comments-sought-on-drug-ad-information-requirements/)  
*Federal Register* notice: FDA seeks comments on an information collection for “Prescription Drug Advertisements.” 08/08/2017

[**48 ANDA Bioequivalence Guidances Published**](https://www.fdaweb.com/48-anda-bioequivalence-guidances-published/)  
*Federal Register* notice: FDA announces the availability of 48 final product-specific guidances that recommend the design of bioequivalence studies to support ANDAs. 08/07/2017

[**Oncologic Drugs Panel to Review Sutent sNDA**](https://www.fdaweb.com/oncologic-drugs-panel-to-review-sutent-snda/)  
*Federal Register* notice: FDA announces a 9/19 Oncologic Drugs Advisory Committee meeting to review a C.P. Pharmaceuticals supplemental NDA for Sutent. 08/07/2017 

[**Vaccines Panel to Review Glaxo Zoster Vaccine**](https://www.fdaweb.com/vaccines-panel-to-review-glaxo-zoster-vaccine/)  
*Federal Register* notice: FDA announces a 9/13 Vaccines and Related Biological Products Advisory Committee meeting that will review GlaxoSmithKline Biologicals’ zoster vaccine recombinant. 08/07/2017